Gilead Sciences might have expected a hepatitis C patent challenge in India. But in Europe? Not so much. But that's exactly what Gilead is getting. After losing its bid for a new Indian patent covering its blockbuster treatment Sovaldi, Gilead is now threatened with a similar action at the European Patent Office in Munich.
Pharma analysts have different opinions on how much branded drugmakers will feel the heat from biosimilars--and when they'll feel it. But according to one Citi analyst, they're all underestimating the impact on AbbVie's top dog.
Good news for Teva when it comes to Mylan's generic version of AstraZeneca's Nexium: It won't be around for a little while.
Novartis and its Neupogen biosimilar are steamrolling toward the U.S. market. But Amgen hasn't given up stopping the product in its tracks. The biotech last week urged a California court to block the biosimilar launch, with FDA approval expected as soon as March 9.
SINGAPORE--Singapore plans to offer a version of universal healthcare that builds on catastrophic insurance mandatory under the country's Central Provident fund.
SINGAPORE--A proposed $200 million merger between India's Strides Arcolab and Shasun Pharmaceuticals is about to be tested by Shasun's shareholders.
FiercePharma brings you notes on the Asian and emerging markets operations of major drug companies from fourth-quarter earnings calls to explain what C-suite executives are focused on.
Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment Benicar set to lose patent protection next year. A black-box warning on its new drug Savaysa isn't helping matters. So analysts are wondering what the company can do to plug the forthcoming sales holes.
Look for some big changes next time you run across a magazine ad for Crestor or Viagra or any of the brands on heavy rotation. The FDA has decided that its long-standing disclose-all policy on side effects was wrong. Way wrong.
SINGAPORE--The head of Guinea's Ebola-response program wasted no time in announcing approval of broader use of Fujifilm's Avigan (favipiravir) influenza drug for treating early cases of Ebola in the West Africa nation.
Roche now has another approval under its belt for eye drug Lucentis. And it's in a market it can call its own: Lucentis is the first U.S.-approved treatment for diabetic retinopathy in patients with diabetic macular edema.
SINGAPORE--Pakistan's pharmaceutical industry reportedly has decided to step aside and cease opposition to a government plan to force down the price of certain drugs marketed in the country as of July 1, 2016.
Novo Nordisk has joined the spinoff club. The Danish drugmaker says it's ready to let its information technology unit, NNIT, go solo via an initial public offering.
SINGPAPORE--Merck has confirmed it will move to let Simcere Pharmaceuticals run a high-profile China joint venture aimed at branded generic drugs announced in 2011 and focus instead on its mature products in the local market.
GlaxoSmithKline's job-chopping ax has struck Hamilton, MT, where 27 vaccine researchers will pack up this year. The pharma giant plans to centralize its R&D efforts in one location, but where that will be hasn't yet been decided, company spokeswoman Melinda Stubbee told local paper Missoulian.
Pfizer may have agreed on Thursday to pick up injectable drugmaker Hospira for $17 billion, but don't expect it to stop its dealmaking there, analysts say.
Shire's Dublin, Ireland, address has made the specialty drugmaker a prime takeover target. Now Shire's own use of a tax haven has made it exhibit A in a dust-up over tax shelters being investigated in the U.K.
Arkansas Medicaid officials have wrapped up a legal dispute over Vertex's cystic fibrosis drug Kalydeco, settling to resolve claims the state denied patients the treatment based on its high price tag. And while it's good news for the drugmaker, this may be just the first in a series of cost-control battles to follow.
In four years as CEO of Hospira, F. Michael Ball has moved the company from its quality quagmire and a stock price collapse to an injectable drug leader and biosimilar player significant enough to be a prize worthy of a $15 billion buyout offer from Pfizer. People who make predictions about these kinds of things say Ball's rehab of Hospira would make him in big demand to run another company in need of a makeover.
Setting up camp in the Middle East is the trend du jour in Big Pharma, and Merck KGaA is expanding its footprint there by launching its new diabetes education program in the United Arab Emirates.